Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 10/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 10/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25793793 | 0.91 | ALDH1A1 (0.50) | DNM1ALDH1A1TSHRPAOXKDM4A | |
| SCHEMBL18762845 | 0.87 | ALDH1A1 (0.47) | TDP1DNM1ALDH1A1TSHRPAOX | |
| SCHEMBL11464815 | 0.84 | — | — | |
| SCHEMBL9670739 | 0.84 | ALDH1A1 (0.45) | TDP1DNM1ALDH1A1TSHRPAOX | |
| SCHEMBL28430391 | 0.79 | DNM1 (0.59) | TDP1DNM1ALDH1A1TSHR | |
| SCHEMBL29125639 | 0.79 | DNM1 (0.59) | TDP1DNM1ALDH1A1TSHR | |
| SCHEMBL28483282 | 0.79 | DNM1 (0.59) | TDP1DNM1ALDH1A1TSHR | |
| SCHEMBL22462118 | 0.79 | DNM1 (0.59) | TDP1DNM1ALDH1A1TSHR | |
| SCHEMBL18762844 | 0.79 | ALDH1A1 (0.53) | DNM1ALDH1A1TSHRPAOXKDM4A | |
| SCHEMBL21391387 | 0.78 | PAOX (0.44) | TDP1ALDH1A1PAOXKDM4CKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606030-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | Indoco Remedies Limited (IN) | 2013-06-26 | — | — | EP | claimed |
| WO-2012023147-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | INDOCO REMEDIES LIMITED (IN) | 2012-02-23 | — | — | WO | claimed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9115093-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-20140249129-A1 | Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-04 | — | — | US | disclosed |
| US-7851439-B2 | EFTU inhibitors or aminothiazoles and their uses | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-20100267757-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | PSMG3, HSPA5, TTR | TDP1 1328/4885DNM1 1347/4885ALDH1A1 4128/4885 |
| US-20140249129-A1 | Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity | SERPINB1, ELANE, MPO | TDP1 883/4885DNM1 4409/4885ALDH1A1 109/4885 |
| US-20100267757-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, GOT2 | TDP1 1091/4885DNM1 2575/4885ALDH1A1 353/4885 |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | LPO, PCNA, BPGM | TDP1 1802/4885DNM1 1409/4885ALDH1A1 1404/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | TDP1 1010/4885DNM1 4341/4885ALDH1A1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.